Sciclone Pharmaceuticals (SCLN) 8-K Sciclone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance

Global Strategies for

Life-Enhancing Drugs

Corporate Presentation

January 2010

Exhibit 99.2

Safe Harbor Statement

This presentation contains forward-looking statements regarding development

objectives and timing expectations.  You are urged to consider statements that

include the words "may," "will," "would," "could," "should," "might," "believes,"

"estimates," "projects," "potential," "expects," “potential,”

"plans," "anticipates,"

"intends," "continues," "forecast," "designed," "goal,“

“unaudited,”

“approximately,”

or the negative of those words or other comparable words to be uncertain and

forward-looking.  These statements are subject to risks and uncertainties that are

difficult to predict and actual outcomes may differ materially. These risks include the

outcome of Chinese governmental processes and decisions and our ability to

respond to those decisions, as well as the response of manufacturers of generic

thymosin

alpha-1. These risks and uncertainties also include our ability to identify

and consummate our previously-announced goals of acquiring additional products

to sell, either through licensing or the acquisition of businesses.  Please also refer to

other risks and uncertainties described in SciClone's

filings with the SEC. All

forward-looking statements are based on information currently available to SciClone

and SciClone

assumes no obligation to update any such forward-looking statements.

2

Global Specialty Pharma Company

Profit-driven and Growing

•

Significant profitability and cash flow positive

•

2009 financial results and outlook:

•

Approximately $72.4 MM revenue (unaudited); 34% increase

•

Approximately $31.8 MM cash & investments (unaudited) at 12/31/09

•

$0.18 -

$0.22 current EPS guidance (complete results coming later this quarter)

•

2010 revenue guidance  $82 –

$85 MM; approximately 15% increase

•

Revenue growth + tight expense management = positive EPS year-over-year

•

International Commercial Success

•

Established business in China with a strong, efficient sales organization

•

Strong international brand recognition

•

Plans to further build China business:

•

Active

in-licensing

program;

DC

Bead™

&

RapidFilm™

•

M&A; significant effort underway

•

ZADAXIN

®

marketed in more than 30 countries

•

Rich Product Portfolio in Oncology and Infectious Disease

•

Invest in cost-efficient phase 1 and 2 trials; partner at phase 3 stage

•

1 marketed product; developing 2 molecules in 4 indications

3

4

Committed to Sustained Profitability and

Growing EPS

•

Revenue of $72.4 MM A**

2009 Financial Results and Outlook

•

EPS: $0.18 to $0.22 E**

•

Cash and investments of $31.8 MM A**

* 2006 EPS do not include $8MM settlement received that year

**A

–

Actual

(unaudited);

E

-

Estimate

$.0

$20.0

$40.0

$60.0

$80.0

$100.0

2006

2007

2008

2009 A**

2010 E**

Revenue (MM)

EPS:

($.16)*

($.22)

($.18)

$0.18 -

$0.22 E

Specialty Pharma Focus in China:

Significant Growth Opportunity

for SciClone

$60-62

6

•

Chinese Pharmaceutical Market

•

China expected to rank among the top five global pharmaceutical markets by 2012

and 2nd in market size growth

•

Growth of approximately 23%* over the next three years

•

Our Position/Opportunity

•

Longstanding presence in China since ZADAXIN launched in 1996

•

China 2009 sales >$69 MM

•

1

st

class brand:

•

SciClone

and ZADAXIN well-regarded by physician community;

•

Western manufacturing seal of approval

•

Strong sales infrastructure in place

•

Our Growth Strategy

•

Introducing additional products through in-licensing and M&A

•

Commercialization

rights

to

the

anti-nausea

drug

ondansetron

RapidFilm

•

Commercialization rights to embolic agent DC Bead

•

Markets: Hepatitis, cancer populations, infectious diseases

•

Expanding hospital coverage in tier 2 and 3 cities

Growth Opportunity: SciClone

in China

*  McKinsey, 2009

7

•

Thymosin

alpha 1 (ZADAXIN generic name) included in Class B of

China’s National Drug Reimbursement List (“NDRL”) in November 2009

•

NDRL consists of >2,100 drugs

•

Important component of the healthcare reform plan in China

•

Government aiming for universal healthcare coverage by 2012

•

Government to reimburse at least part of the cost of the drug

•

Set maximum price that will apply in most circumstances

•

Reimbursement and pricing provisions not expected to go into effect

until 2H 2010, though the timing and outcome of any pricing decision is

uncertain

•

Expanded access should help support SciClone’s

ongoing efforts to

further expand the reach of ZADAXIN in China

China Healthcare Reform Plan Update

Product Portfolio

Product Development

Phase 1

Phase 2

Phase 3

Marketed

Ondansetron

RapidFilm

™

China & Vietnam

Italy & 12 countries; global

H1N1 Vaccine Enhancement

ZADAXIN

®

HBV/HCV & Other Indications

China, Russia & >30 other countries

DC Bead™

China

SCV-

07

HCV

Global (Ex-Russia)

Stage IV Melanoma

U.S./Europe

Palliative care

8

Marketing approval

expected 2011

Marketing approval

expected 2010

Marketing approval

targeted 1H 2010

Liver cancer

Oral Mucositis

in Head/Neck Cancer

Global (Ex-Russia)

ZADAXIN Development Opportunity:

A High Value Drug for H1N1

ZADAXIN Enhancement of Vaccine for H1N1

Virus

Description

and MOA

•

ZADAXIN, a synthetic preparation of naturally

occurring

peptide

with

immunostimulatory

activity

which

promotes antibody production

•Potential to develop ZADAXIN as an enhancer of novel

H1N1 flu vaccines globally

•

Targeting immune compromised population

•

Approvals in Italy and 12 other countries for influenza

vaccine enhancer indication (6-8 injections)

Commercial

Opportunity

•

Pursuing extension of existing label in Italy

•

Emergency approval procedures now in place in most

countries

•

Potential to expand from Italy to EU, ROW

10

11

ZADAXIN Enhancement of Vaccine for H1N1

Virus

Development

Strategy

•Targeting a new dosage regimen effective with one or

two injections

•

Preclinical studies completed in late 2009

•

Clinical studies underway in Italy

•

Using H1N1 vaccine -

Novartis Focetria™

Future

Development

•

Past experience showed there may be increased

demand if virulence/lethality worsens

•

Similar to SARS experience   

•Longer-term opportunity to become part of seasonal

flu vaccination regimen for immune compromised

populations

Phase 2 Drug Candidate in

Two Indications: SCV-07

13

SCV-07: Phase 2 Oral Mucositis

(OM)

Opportunity

Description

and MOA

•

Novel dipeptide

inhibits STAT-3 signaling leading to

dendritic

cell maturation and increased Th1 cytokine

production

•

Restores balance in Th1/Th2 helper T cell ratio (ratio

shifted to Th2 by radiation)

•

Subcutaneously as well as orally available

Commercial

Opportunity

•OM after chemoradiation: Vast unmet medical need

•

Debilitating side effects, including pain, inability to swallow;

complications from feeding tubes and extra medical care

•400,000* head and neck cancer patients in the U.S.

•Exclusive worldwide rights, excluding Russia

*Source: NCI

14

SCV-07: Phase 2 Oral Mucositis

Opportunity

Development

Strategy

•

Double-blind, placebo controlled, phase 2 trial  to delay

the onset of severe OM in head and neck cancer patients

and decrease its severity

•

Enrollment completed in 2H 2009

Future

Development

•

Topline

results to be reported in 1H 2010

•

Opportunity

to

prevent

mucositis

from

chemoradiation

in 

other oncology indications

15

SCV-07: Phase 2 HCV Opportunity

Description

and MOA

•

Novel dipeptide

inhibits STAT-3 signaling leading to

dendritic

cell maturation and increased Th1 cytokine

production

•

Increases Th1-type immune responses (Th1 responses

needed for viral clearance of infected cells)

•

Subcutaneously as well as orally available

Commercial

Opportunity

•

HCV represents large unmet medical need; market size

>$2 B* in 2008; expected to grow to >$10 B* within 5-7 yrs

•

Interferon has significant side effects and SOC leads to

<50% sustained responses

•

Limited drugs under development for interferon

replacement

•

Most drugs in development are direct antivirals

* Source: Decision Resources, Data Monitor

16

SCV-07: Phase 2 HCV Opportunity

Development

Strategy

•

Initial

7

day

monotherapy

study

reported

at

EASL

showed SCV-07 is safe

•

Viral load reduction and increased biomarker (neopterin)

of macrophage activation seen in some patients

•

Phase

2

trial

of

SCV-07

lead-in

monotherapy

followed

by combination therapy with ribavirin

in patients with

genotype 1 chronic HCV; relapsed to SOC

•

Trial initiated in 2H 2009 

•

Topline

results to be reported in 2H 2010

Future

Development

•

Demonstrate a clinically-relevant result in phase 2

•

Follow up with additional Phase 2 trial including a STAT-

C drug demonstrating SVRs

superior to or comparable to

SOC but with none of the interferon-type toxicity

17

DC Bead: Targeting Liver Cancer in China

Description

•

Embolic agent, delivers chemotherapy drugs

•

Microscopic beads with dual anti-tumor effects

•

Deliver doxorubicin, potentially other chemotherapy

agents directly to tumor

Commercial

Opportunity

•

Exclusive Chinese marketing rights

•

Market-specific unmet need; Liver cancer one of most

prevalent and deadly cancers in China

•

271,300 diagnosed population; 64,530 drug-treated

population

•

Leverage existing brand image, marketing and

distribution channels, and strong in-country sales

expertise

18

Ondansetron

RapidFilm™

Description

•

Serotonin 5-HT3 receptor antagonist commonly used to

treat and prevent nausea and vomiting caused by

chemotherapy, radiotherapy, and surgery

•

Innovative oral thin film formulation of ondansetron

Commercial

Opportunity

•

Commercialization rights in China and Vietnam

•

2008 sales of serotonin 5-HT3Serotonin receptor

antagonists reached more than $110 million in China

•

RapidFilm

delivery provides improvements over generic

and branded formulations of intravenous and oral tablet

ondansetron

* Source: Decision Resources, Data Monitor

Corporate Progress

20

Milestones

Milestone

Timeline

2009 revenue guidance $70-$72 MM; $72.4 MM Actual

Completed

Complete preclinical studies evaluating the treatment regimen for

ZADAXIN as an enhancer of H1N1 pandemic flu vaccine

Completed

Initiate clinical studies evaluating the treatment regimen for ZADAXIN as

an enhancer of H1N1 pandemic flu vaccine

Completed

SCV-07

phase

2

trial

in

oral

mucositis

complete

enrollment

Completed

ZADAXIN

H1N1

clinical

study

topline

results

Early 2010

SCV-07 phase 2 trial in HCV complete enrollment

1H 2010

SCV-07 phase 2 oral mucositis

topline

results data

1H 2010

Achieve regulatory approval for DC Bead in China

2H 2010

Establish

partnership

for

Phase

3-ready

thymalfasin

product

candidate

in stage IV melanoma; active discussions ongoing

Ongoing

2010 revenue guidance $82-$85 MM

Ongoing

21

Global Specialty Pharma Company

Profit-driven and Growing

•

Significant profitability and cash flow positive

•

2009 financial results and outlook:

•

Approximately $72.4 MM revenue (unaudited); 34% increase

•

Approximately $31.8 MM cash & investments (unaudited) at 12/31/09

•

$0.18 -

$0.22 current EPS guidance (complete results coming later this quarter)

•

2010

revenue

guidance

$82

–

$85

MM;

approximately

15%

increase

•

Revenue growth + tight expense management = positive EPS year-over-year

•

International Commercial Success

•

Established business in China with a strong, efficient sales organization

•

Strong international brand recognition

•

Plans to further build China business:

•

Active in-licensing program; DC Bead & RapidFilm

•

M&A; significant effort underway

•

ZADAXIN marketed in more than 30 countries

•

Rich Product Portfolio in Oncology and Infectious Disease

•

Invest in cost-efficient phase 1 and 2 trials; partner at phase 3 stage

•

1 marketed product; developing 2 molecules in 4 indications

Global Strategies for

Life-Enhancing Drugs

Corporate Presentation

January 2010